BioProcess Technology Consultants, Inc. Announces Business Development Consulting Agreement with Angel Biotechnology Ltd
Published: Jul 14, 2011
“We are pleased to be working with Angel to offer business development assistance as well as technical and manufacturing support to the growing number of US cell therapy companies,” said Howard L. Levine, Ph.D., BPTC President and Principal Consultant. “The need to manufacture these products in a fully cGMP compliant facility to ensure reliable and reproducible treatments for patients is essential as they progress through rigorous clinical development and eventual commercialization. BPTC recognizes the need for experienced contract manufacturers to assist companies in meeting the unique manufacturing, quality, and regulatory challenges of these products. As a leader in providing these services to cell therapy companies, Angel is an ideal partner to assist North American companies developing cell therapy products. With our proprietary database of biopharmaceutical products in development and our network of North American industry contacts, we are uniquely positioned to assist Angel in identifying new clients for its cell therapy manufacturing services,” added Dr. Levine.
“We look forward to harnessing BPTC’s wealth of industry experience and expertise to enhance our marketing strategy for the North American cell therapy manufacturing market,” said Gordon Sherriff, Chief Operating Officer of Angel Biotechnology Holdings Plc. “Having such a talented and highly regarded biotechnology consulting company as our partner in this key market is a significant step forward for Angel. BPTC’s vast network of industry connections, especially in the North American biotech market, will provide key contacts with potential new clients to accelerate the growth of Angel’s pipeline of cell therapy contracts.”
About BioProcess Technology Consultants
Founded in 1994, BPTC is the recognized worldwide leader in biologics CMC consulting, providing a full range of technical, regulatory, and strategic assistance to biopharmaceutical and biotechnology companies in the development and commercialization of biopharmaceutical products. BPTC works with companies to find solutions to the challenges of biopharmaceutical product development from clone to commercial®. BPTC specializes in developing effective and efficient manufacturing processes and strategies and assists companies develop product discovery and process development programs that enhance their overall value. Recognizing the parallels between today’s cell therapy manufacturing hurdles and the early days of recombinant protein production, BPTC has begun to apply its skills and expertise in bioprocessing, Quality, and CMC regulatory to assist companies developing these cutting edge technologies. BPTC also helps investors make informed decisions by providing technical and business evaluations of new products and technologies and product discovery, development, and commercialization plans of potential investments and existing portfolio companies. For more information about BPTC, visit http://www.bptc.com and follow the Company on Twitter at bptcGlobal or LinkedIn at http://www.linkedin.com/company/bioprocess-technology-consultants-inc.
About Angel Biotechnology Holdings Plc
Angel Biotechnology Holdings Plc is a full service contract bio-manufacturing partner to biotechnology and pharmaceutical companies worldwide. Angel specializes in advanced biologics including biopharmaceutical proteins and cell therapies, such as cellular vaccines and stem cells. At present, Angel’s products are principally used in pre-clinical studies and clinical trials with a view to becoming the contract manufacturer of choice on a continuing basis.
Drug development companies outsource their biopharmaceutical manufacturing requirements to Angel to reduce their own capital requirements and enable them to develop products more rapidly. In addition, Angel provides complete regulatory services and documentation to its customers while its manufacturing processes adhere to the most stringent regulatory requirements. Products are produced to current Good Manufacturing Practice (cGMP) standards as required by the US Food and Drug Administration (FDA), and in facilities that are certified to European standards by the Medicines and Healthcare products Regulatory Agency (MHRA). For media inquiries, please contact Ariane Comstive or Caolan Mahon at +44 (0) 20 7536 2028 / 2029 or email@example.com